Clearside Biomedical, Inc. (CLSD) Director Clay Thorp Sells 15,000 Shares of Stock

Clearside Biomedical, Inc. (NASDAQ:CLSD) Director Clay Thorp sold 15,000 shares of the company’s stock in a transaction on Tuesday, November 14th. The shares were sold at an average price of $7.02, for a total value of $105,300.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Clay Thorp also recently made the following trade(s):

  • On Thursday, November 16th, Clay Thorp sold 35,000 shares of Clearside Biomedical stock. The shares were sold at an average price of $7.00, for a total value of $245,000.00.
  • On Thursday, October 5th, Clay Thorp sold 35,000 shares of Clearside Biomedical stock. The shares were sold at an average price of $8.57, for a total value of $299,950.00.
  • On Thursday, September 14th, Clay Thorp sold 6,000 shares of Clearside Biomedical stock. The shares were sold at an average price of $7.52, for a total value of $45,120.00.
  • On Wednesday, September 13th, Clay Thorp sold 8,500 shares of Clearside Biomedical stock. The shares were sold at an average price of $7.49, for a total value of $63,665.00.
  • On Friday, September 15th, Clay Thorp sold 24,500 shares of Clearside Biomedical stock. The stock was sold at an average price of $7.52, for a total value of $184,240.00.

Clearside Biomedical, Inc. (NASDAQ:CLSD) traded up $0.13 during trading on Friday, hitting $7.09. The stock had a trading volume of 100,218 shares, compared to its average volume of 154,013. The company has a quick ratio of 4.57, a current ratio of 4.57 and a debt-to-equity ratio of 0.15. Clearside Biomedical, Inc. has a 12 month low of $5.44 and a 12 month high of $24.73.

Clearside Biomedical (NASDAQ:CLSD) last posted its quarterly earnings results on Wednesday, November 8th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.17). Clearside Biomedical had a negative return on equity of 90.72% and a negative net margin of 17,684.07%. The business had revenue of $0.16 million for the quarter, compared to analyst estimates of $0.01 million. research analysts forecast that Clearside Biomedical, Inc. will post -2.25 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Transcript Daily and is owned by of Transcript Daily. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://transcriptdaily.com/2017/11/18/clearside-biomedical-inc-clsd-director-clay-thorp-sells-15000-shares-of-stock.html.

A number of institutional investors and hedge funds have recently modified their holdings of CLSD. Wells Fargo & Company MN increased its holdings in Clearside Biomedical by 325.0% in the 1st quarter. Wells Fargo & Company MN now owns 16,739 shares of the company’s stock worth $133,000 after purchasing an additional 12,800 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Clearside Biomedical by 10.8% in the 1st quarter. Bank of New York Mellon Corp now owns 34,823 shares of the company’s stock worth $277,000 after purchasing an additional 3,404 shares in the last quarter. JPMorgan Chase & Co. acquired a new position in Clearside Biomedical in the 1st quarter worth about $178,000. TIAA CREF Investment Management LLC increased its holdings in Clearside Biomedical by 30.7% in the 1st quarter. TIAA CREF Investment Management LLC now owns 19,257 shares of the company’s stock worth $153,000 after purchasing an additional 4,527 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new position in Clearside Biomedical in the 1st quarter worth about $604,000. 52.55% of the stock is owned by institutional investors and hedge funds.

CLSD has been the subject of a number of research analyst reports. TheStreet cut Clearside Biomedical from a “c-” rating to a “d” rating in a report on Friday, August 11th. Cowen and Company reissued a “buy” rating on shares of Clearside Biomedical in a report on Wednesday, October 25th. Zacks Investment Research raised Clearside Biomedical from a “sell” rating to a “hold” rating in a report on Wednesday, October 25th. Finally, ValuEngine cut Clearside Biomedical from a “hold” rating to a “sell” rating in a report on Thursday, August 10th. Two research analysts have rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $18.33.

About Clearside Biomedical

Clearside Biomedical, Inc is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment.

Insider Buying and Selling by Quarter for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Ratings for Clearside Biomedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply